Navigation Links
Monogram Announces 2008 Second Quarter Financial Results
Date:7/29/2008

al approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether existing levels of reimbursement will be reviewed and reduced by third party payers, including Medicare; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, G.E. and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense, PhenoSenseGT, Trofile, HERmark and VeraTag are trademarks of Monogram Biosciences, Inc. Hercept
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 With ... us, it is welcome news that a fire ... than current protection is under development by SunSeeker Enterprises, ... NASA to protect spacecraft from the extreme heat of ... to both firefighters and homes. , “Our firefighters routinely ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
(Date:7/28/2014)... from The University of Texas Health Science Center at San ... a combination of pills that cures 9 of 10 hepatitis ... simeprevir, with or without ribavirin, cured 93 percent of patients ... to the study published today in The Lancet . ... , Eric Lawitz, M.D., clinical professor in the School of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- A ... stiffness in older people may increase the risk ... suggests. A British study found that patients ... vascular disease -- conditions that affect the blood ... factors of patients with polymyalgia rheumatica to reduce ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... dating has not only shed its stigma, it has ... other than meeting through friends, according to a new ... The digital revolution in romance is a boon ... potential partners, reports the team of psychological scientists who ...
... , FRIDAY, Feb. 3 (HealthDay News) -- ,Extended synaptic development ... new study suggests. During the first few years of ... information and experiences from the environment in a way that ... This is due to extended synaptic development, according to the ...
... been mapped with unprecedented accuracy in the bloodstream of ... brand new approach, in an attempt to assess and ... through the body, and solve the problem of predicting ... to a previous generation of systems, the researchers state ...
... aged 70 and over will increase by 40% in ... over will more than double1. Health authorities and the ... of people suffering costly and debilitating age-related chronic diseases ... dementia. The significant increase in the numbers of people ...
... (February 1, 2012) Rates of diabetes vary widely across ... by Dr. Longjian Liu of Drexel University,s School of ... diabetes now live in developing countries. Liu,s study found ... in developing countries, and that one in 10 diagnosed ...
... , THURSDAY, Feb. 2 (HealthDay News) -- Sometimes, there,s nothing ... that where the itch resides is key to ... understanding of itch and might even help folks battling itchy ... professor of dermatology at Wake Forest Baptist Medical Center in ...
Cached Medicine News:Health News:Online dating research shows cupid's arrow is turning digital 2Health News:Online dating research shows cupid's arrow is turning digital 3Health News:Why Human Brains Are Smarter Than Chimp Brains 2Health News:New technology to tackle treatment-resistant cancers 2Health News:New study to assess 3 simple, cost-effective strategies to promote healthy aging 2Health News:Diabetes rates vary widely in developing countries, 1 in 10 cases untreated 2Health News:Pleasure in Scratching an Itch May Depend on Location 2
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... 2014 Research and Markets  has announced the ... report to their offering. ... leads to inflammation and pain in the human body,s joints ... it causes inflammation of the tissues that surround the joints ... of RA begin slowly, usually just mild pain around the ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... and Only Approved Platelet Producer in Europe Represents ... Switzerland, Feb. 6 Amgen (Nasdaq: ... (EC) has granted marketing authorisation for Nplate(R) (romiplostim) ... (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory ...
... CAMBRIDGE, Mass. and LONDON, Feb. 6 Idenix Pharmaceuticals, ... today announced the execution of a license agreement granting ... a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase ... treatment of HIV/AIDS. New NNRTIs are needed to ...
Cached Medicine Technology:Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 2Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 3Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 4Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 5
... cervical stabilization from neutral to ... widening under occiput when collar ... fasterner.,Exo-Static™ Collar with Chin Piece ... neutral position and restricts lateral ...
... Padding&trade is perfect for use for lightweight ... materials or used to line braces, prosthetics, ... against shock and vibration and conforms to ... and chaffing. It is a 2mm thick ...
... support and stabilization for muscles and ligaments ... pain and discomfort. Strong elastic abdominal ... for varying degrees of compression. Two ... for extra-firm support. Tapered in front ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: